TrialThe Lancet. Oncology2024

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

Philippe Moreau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.